Literature DB >> 10652202

Activin A is an essential cofactor for osteoclast induction.

K Fuller1, K E Bayley, T J Chambers.   

Abstract

Recently, receptor activator of NF-kappaB ligand (RANKL) was shown to be necessary for osteoclast formation. We now report that activin A, a cytokine enriched in bone matrix and secreted by osteoblasts and osteoclasts, powerfully synergized with RANKL for induction of osteoclast-like cells (OCL) from bone marrow precursors depleted of stromal cells. Moreover, OCL formation in RANKL was virtually abolished by soluble type II A activin receptors (ActR-II(A)), suggesting that activin A is essential for OCL formation. Activin A was most effective when precursors were exposed to RANKL and activin A simultaneously: resistance to OCL-induction that occurs when precursors are pre-incubated in M-CSF was reduced. Incubation on bone matrix also enhanced the sensitivity of precursors to OCL-induction by RANKL; and this was prevented by soluble ActR-II(A). Thus, activin A in bone matrix, or released from osteoblastic or other cells, enhances the osteoclast-forming potential of precursors and synergizes with RANKL in inducing osteoclastic differentiation. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10652202     DOI: 10.1006/bbrc.2000.2075

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  35 in total

1.  Activin A suppresses osteoblast mineralization capacity by altering extracellular matrix (ECM) composition and impairing matrix vesicle (MV) production.

Authors:  Rodrigo D A M Alves; Marco Eijken; Karel Bezstarosti; Jeroen A A Demmers; Johannes P T M van Leeuwen
Journal:  Mol Cell Proteomics       Date:  2013-06-17       Impact factor: 5.911

Review 2.  Activins and Inhibins: Roles in Development, Physiology, and Disease.

Authors:  Maria Namwanje; Chester W Brown
Journal:  Cold Spring Harb Perspect Biol       Date:  2016-07-01       Impact factor: 10.005

3.  Skeletal Response to Soluble Activin Receptor Type IIB in Mouse Models of Osteogenesis Imperfecta.

Authors:  Youngjae Jeong; Salah A Daghlas; Yixia Xie; Molly A Hulbert; Ferris M Pfeiffer; Mark R Dallas; Catherine L Omosule; R Scott Pearsall; Sarah L Dallas; Charlotte L Phillips
Journal:  J Bone Miner Res       Date:  2018-06-22       Impact factor: 6.741

4.  Bone anabolic agents for the treatment of multiple myeloma.

Authors:  Sonia Vallet; Noopur Raje
Journal:  Cancer Microenviron       Date:  2011-12-03

5.  Circulating follistatin in patients with chronic kidney disease: implications for muscle strength, bone mineral density, inflammation, and survival.

Authors:  Tetsu Miyamoto; Juan Jesús Carrero; Abdul Rashid Qureshi; Björn Anderstam; Olof Heimbürger; Peter Bárány; Bengt Lindholm; Peter Stenvinkel
Journal:  Clin J Am Soc Nephrol       Date:  2011-02-24       Impact factor: 8.237

6.  Mechanisms of multiple myeloma bone disease.

Authors:  Deborah L Galson; Rebecca Silbermann; G David Roodman
Journal:  Bonekey Rep       Date:  2012-08-01

Review 7.  Regulation of osteoblastogenesis and osteoclastogenesis by the other reproductive hormones, Activin and Inhibin.

Authors:  Kristy M Nicks; Daniel S Perrien; Nisreen S Akel; Larry J Suva; Dana Gaddy
Journal:  Mol Cell Endocrinol       Date:  2009-07-15       Impact factor: 4.102

8.  Overexpression of BMP3 in the developing skeleton alters endochondral bone formation resulting in spontaneous rib fractures.

Authors:  Laura W Gamer; Karen Cox; Joelle M Carlo; Vicki Rosen
Journal:  Dev Dyn       Date:  2009-09       Impact factor: 3.780

Review 9.  The effects of proteasome inhibitors on bone remodeling in multiple myeloma.

Authors:  Maurizio Zangari; Larry J Suva
Journal:  Bone       Date:  2016-03-03       Impact factor: 4.398

10.  Circulating activin-A is elevated in postmenopausal women with low bone mass: the three-month effect of zoledronic acid treatment.

Authors:  A D Anastasilakis; S A Polyzos; P Makras; A Gkiomisi; M Savvides; A Papatheodorou; E Terpos
Journal:  Osteoporos Int       Date:  2012-11-03       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.